8-K Announcements
6Material company update
Mar 5, 2026·SEC
Material company update
Dec 3, 2025·SEC
Material company update
Nov 19, 2025·SEC
ZyVersa Therapeutics, Inc.(ZVSA)Earnings, Financials & Key Ratios
ZVSA•NASDAQ
$0.20
$1.19B mkt cap·Price updated May 14, 2026
AboutZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.Show more
- Revenue$0
- EBITDA-$25M+99.7%
- Net Income-$24.95B-165.1%
- EPS (Diluted)-4.18+50.7%
- Interest Coverage-49.28+99.9%
ZVSA Key Insights
ZyVersa Therapeutics, Inc. (ZVSA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 355.8% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ZVSA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ZVSA Price & Volume
ZyVersa Therapeutics, Inc. (ZVSA) stock price & volume — 10-year historical chart
Loading chart...
ZVSA Growth Metrics
ZyVersa Therapeutics, Inc. (ZVSA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-165.07%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM66.89%
Return on Capital
10 Years-28631.22%
5 Years-28631.22%
3 Years-42932.68%
Last Year-
ZVSA Peer Comparison
ZyVersa Therapeutics, Inc. (ZVSA) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 371.02M | 3.40 | -1.69 | -70.79% | 0.09 | |||
 PRAX | 9.98B | 345.52 | -25.63 | -100% | -43.02% | 0.00 | ||
 IMVT | 5.89B | 28.96 | -10.61 | -47.07% | 0.00 | |||
 VKTX | 3.67B | 31.71 | -9.94 | -71.31% | 0.00 | |||
 ALDX | 99.87M | 1.66 | -1.77 | -87.71% | 0.22 | |||
 ARQT | 2.7B | 21.57 | -165.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 RARE | 2.54B | 25.80 | -4.43 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 |
Compare ZVSA vs Peers
ZyVersa Therapeutics, Inc. (ZVSA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZVSA Income Statement
ZyVersa Therapeutics, Inc. (ZVSA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 10.4K | 10.4K | 10.4K | 10.4K | 6.93K | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | -10.4K▲ 0% | -10.4K▲ 0.0% | -10.4K▲ 0.0% | -10.4K▲ 0.0% | -6.93K▲ 33.3% | 0▲ 100.0% |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | 0% | 0% | 0% | 33.34% | 100% |
| Operating Expenses | 11.83M | 7.7M | 13.82M | 14.41M | 9.13M | 6.84M |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 5.36M | 5.58M | 7.61M | 11.2M | 7.36B | 5.73B |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 6.47M | 2.12M | 5.41M | 3.21M | 1.78B | 1.11B |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 809.67K | 0 | -9.13B | -6.84B |
| Operating Income | -11.83M▲ 0% | -7.7M▲ 34.9% | -13.83M▼ 79.5% | -14.42M▼ 4.2% | -9.14B▼ 63258.8% | -6.84M▲ 99.9% |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | 34.89% | -79.55% | -4.25% | -63258.83% | 99.93% |
| EBITDA | -11.82M | -7.69M | -13.82M | -14.41M | -9.14B | -25.29M |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | - | 34.92% | -79.66% | -4.25% | -63304.51% | 99.72% |
| D&A (Non-Cash Add-back) | 10.4K | 10.4K | 10.4K | 10.4K | 6.93K | 0 |
| EBIT | -12.17M | -7.26M | -14.44M | -107.75M | -9.15B | -25.29M |
| Net Interest Income | -515.93K | -820.54K | -427.11K | 457 | -269.86K | -513.21K |
| Interest Income | 516 | 821 | 428 | 457 | 0 | 0 |
| Interest Expense | 516.45K | 821.37K | 427.54K | 0 | 269.86K | 513.21K |
| Other Income/Expense | -850.11K | -379.79K | -1.03M | -93.33M | -283.35M | -18.96M |
| Pretax Income | -12.68M▲ 0% | -8.08M▲ 36.3% | -14.87M▼ 83.9% | -107.75M▼ 624.8% | -9.42B▼ 8642.3% | -25.8M▲ 99.7% |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | -745.05K | -9.46M | -6.75M | -851.66K |
| Effective Tax Rate % | 0% | 0% | 5.01% | 8.78% | 0.07% | 3.3% |
| Net Income | -12.68M▲ 0% | -8.08M▲ 36.3% | -14.05M▼ 73.8% | -98.3M▼ 599.7% | -9.41B▼ 9476.4% | -24.95B▼ 165.1% |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | - | 36.26% | -73.77% | -599.75% | -9476.43% | -165.07% |
| Net Income (Continuing) | -12.68M | -8.08M | -14.12M | -98.3M | -9.41B | -24.95M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -272.45▲ 0% | -173.66▲ 36.3% | -930.25▼ 435.7% | -1089.66▼ 17.1% | -8.48▲ 99.2% | -4.18▲ 50.7% |
| EPS Growth % | - | 36.26% | -435.67% | -17.14% | 99.22% | 50.71% |
| EPS (Basic) | -272.45 | -173.66 | -930.25 | -1089.66 | -8.48 | -4.18 |
| Diluted Shares Outstanding | 46.55K | 46.55K | 25.95K | 97.5K | 1.11M | 5.96B |
| Basic Shares Outstanding | 46.55K | 46.55K | 25.95K | 97.5K | 1.11M | 5.96B |
| Dividend Payout Ratio | - | - | - | - | - | - |
ZVSA Balance Sheet
ZyVersa Therapeutics, Inc. (ZVSA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Total Current Assets | 339.11K | 811.78K | 6.36M | 3.35M | 1.72M | 347.9M |
| Cash & Short-Term Investments | 174.67K | 328.58K | 5.9M | 3.14M | 1.53M | 101.78M |
| Cash Only | 174.67K | 328.58K | 5.9M | 3.14M | 1.53M | 101.78M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 164.44K | 483.2K | 460.35K | 215.46K | 184.87K | 246.12M |
| Total Non-Current Assets | 346.46K | 314.39K | 112.14M | 18.76M | 18.88M | 0 |
| Property, Plant & Equipment | 38.13K | 27.73K | 115.7K | 14.77K | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 11.9M | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 100.09M | 18.65M | 18.65M | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 308.32K | 286.66K | 46.66K | 98.48K | 235.71K | 0 |
| Total Assets | 685.57K▲ 0% | 1.13M▲ 64.3% | 118.51M▲ 10422.9% | 22.11M▼ 81.3% | 20.6M▼ 6.9% | 347.9M▲ 1588.9% |
| Asset Turnover | - | - | - | - | - | - |
| Asset Growth % | - | 64.27% | 10422.91% | -81.34% | -6.85% | 1588.89% |
| Total Current Liabilities | 7.56M | 13.63M | 8.19M | 10.19M | 11.23M | 12.73B |
| Accounts Payable | 2.31M | 2M | 6.03M | 8.43M | 9.34M | 10.12M |
| Days Payables Outstanding | 81.14K | 70.2K | 211.48K | 295.92K | 491.58K | - |
| Short-Term Debt | 2.13M | 9.15M | 108.76K | 8.66K | 0 | 0 |
| Deferred Revenue (Current) | 20.5K | 16.91K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.18M | 2.46M | 1.36M | 1.09M | 854.7K | 12.72B |
| Current Ratio | 0.04x | 0.06x | 0.78x | 0.33x | 0.15x | 0.03x |
| Quick Ratio | 0.04x | 0.06x | 0.78x | 0.33x | 0.15x | 0.03x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.69M | 0 | 10.32M | 844.91K | 851.66K | 0 |
| Long-Term Debt | 1.69M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 10.32M | 844.91K | 851.66K | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 9.24M | 13.63M | 18.51M | 11.04M | 12.08M | 12.73B |
| Total Debt | 3.82M | 9.15M | 108.76K | 8.66K | 0 | 0 |
| Net Debt | 3.64M | 8.82M | -5.79M | -3.13M | -1.53M | -101.78M |
| Debt / Equity | - | - | 0.00x | 0.00x | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -23.56x | -8.84x | -33.77x | - | -33908.17x | -49.28x |
| Total Equity | -8.56M▲ 0% | -12.5M▼ 46.1% | 99.99M▲ 899.9% | 11.07M▼ 88.9% | 8.52M▼ 23.1% | -12.39B▼ 145545.5% |
| Equity Growth % | - | -46.07% | 899.95% | -88.92% | -23.1% | -145545.47% |
| Book Value per Share | -183.83 | -268.52 | 3853.64 | 113.58 | 7.67 | -2.08 |
| Total Shareholders' Equity | -8.56M | -12.5M | 99.99M | 11.07M | 8.52M | -12.39B |
| Common Stock | 242 | 242 | 902 | 405 | 251 | 809 |
| Retained Earnings | -44.81M | -52.9M | -4.92M | -103.22M | -112.63M | -137.58M |
| Treasury Stock | 0 | 0 | 0 | -7.17K | -7.17K | -7.17K |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
ZVSA Cash Flow Statement
ZyVersa Therapeutics, Inc. (ZVSA) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Cash from Operations | -5.11M | -5.08M | -4.89M | -8.72M | -7.56M | -5.11B |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | - | 0.66% | 3.69% | -78.39% | 13.31% | -67553.25% |
| Net Income | -12.68M | -8.08M | -14.05M | -98.3M | -9.41M | -24.95B |
| Depreciation & Amortization | 10.4K | 10.4K | 9.87K | 10.4K | 6.93K | 0 |
| Stock-Based Compensation | 3.83M | 4.14M | 3.52M | 1.19M | 705.57K | 222.83M |
| Deferred Taxes | 333.66K | -441.58K | -745.05K | -9.48M | 6.75K | -851.66M |
| Other Non-Cash Items | 288.37K | 317.83K | -1.92M | 95.25M | 204.61K | 20.47B |
| Working Capital Changes | 3.11M | -1.02M | 8.29M | 2.6M | 929.88K | 1.52M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -601.47K | -311.86K | 6.62M | 2.41M | 750.57K | 689.27K |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 4.56M | 5.23M | 1.87M | 5.96M | 5.95M | 3.69B |
| Debt Issued (Net) | 1.69M | 5.23M | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 3M | 0 | 1.87M | 7.41M | 5.95M | 4.05M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -10.7M | 0 | 0 |
| Other Financing | -126.4K | 0 | 0 | -1.46M | 0 | 3.68B |
| Net Change in Cash | -549.76K▲ 0% | 153.91K▲ 128.0% | 5.57M▲ 3521.3% | -2.76M▼ 149.6% | -1.61M▲ 41.9% | -1.43B▼ 88846.4% |
| Free Cash Flow | -5.11M▲ 0% | -5.08M▲ 0.7% | -1.49M▲ 70.6% | -8.72M▼ 483.5% | -7.56M▲ 13.3% | -5.11B▼ 67553.3% |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | - | 0.66% | 70.56% | -483.47% | 13.31% | -67553.25% |
| FCF per Share | -109.77 | -109.04 | -57.60 | -89.44 | -6.81 | -0.86 |
| FCF Conversion (FCF/Net Income) | 0.40x | 0.63x | 0.35x | 0.09x | 0.00x | 0.20x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
ZVSA Key Ratios
ZyVersa Therapeutics, Inc. (ZVSA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -32.11% | -177% | -96099.37% | - |
| Return on Invested Capital (ROIC) | - | - | -22.92% | -21.18% | -91789.94% | - |
| Debt / Equity | - | - | 0.00x | 0.00x | - | - |
| Interest Coverage | -23.56x | -8.84x | -33.77x | - | -33908.17x | -49.28x |
| FCF Conversion | 0.40x | 0.63x | 0.35x | 0.09x | 0.00x | 0.20x |
ZVSA SEC Filings & Documents
ZyVersa Therapeutics, Inc. (ZVSA) SEC filings — annual & quarterly reports (10-K, 10-Q)
ZVSA Frequently Asked Questions
ZyVersa Therapeutics, Inc. (ZVSA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ZyVersa Therapeutics, Inc. (ZVSA) grew revenue by 0.0% over the past year. Growth has been modest.
ZyVersa Therapeutics, Inc. (ZVSA) reported a net loss of $25.0M for fiscal year 2025.
Dividend & Returns
ZyVersa Therapeutics, Inc. (ZVSA) had negative free cash flow of $5.11B in fiscal year 2025, likely due to heavy capital investments.
Explore More ZVSA
ZyVersa Therapeutics, Inc. (ZVSA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates